

Victoria A. Johnson MD

**UNIVERSITY OF ALABAMA AT BIRMINGHAM
SCHOOL OF MEDICINE
FACULTY CURRICULUM VITAE**

PERSONAL INFORMATION

Name: Victoria Anne Johnson, M.D.

Citizen: _____

Social Security #: _____

Home Address: _____

Phone: _____

RANK/TITLE Associate Professor of Medicine and Microbiology

Departments: Medicine and Microbiology

Business Address: University of Alabama at Birmingham School of Medicine
Division of Infectious Diseases
Departments of Medicine and Microbiology
THT 229
1530 3RD AVE S
Birmingham, AL 35294-0006

Phone: _____

Fax: _____

Email: _____

HOSPITAL AND OTHER (NON ACADEMIC) APPOINTMENTS

1991-Present	Attending Physician, Department of Medicine, University of Alabama at Birmingham School of Medicine, Birmingham, Alabama
1991-Present	Staff Physician, Medical Service Infectious Diseases, Department of Veterans Affairs Medical Center, Birmingham, Alabama
1990-1991	Clinical Assistant in Medicine, Massachusetts General Hospital, Boston, Massachusetts
1985-1986	Attending Physician, Department of Medicine, Dartmouth-Hitchcock

Medical Center, Hanover, New Hampshire

1985-1987 **Staff Physician, Medical Service, White River Junction Veterans Affairs Hospital, White River Junction, Vermont**

EDUCATION

1978 **Saint Olaf College
Northfield, Minnesota
Bachelor of Arts, summa cum laude**

1982 **University of Minnesota Medical School
Minneapolis, Minnesota
Doctor of Medicine**

LICENSURE

1990 **Commonwealth of Massachusetts Registration No.**
1991 **State of Alabama Registration No.**

BOARD CERTIFICATION

1983 **Diplomate, National Board of Medical Examiners**
1986 **Diplomate, American Board of Internal Medicine**
1992 **Diplomate, American Board of Internal Medicine, Subspecialty of Infectious Diseases**

POSTDOCTORAL TRAINING

Internship and Residencies:

1982-1983 **Intern, Department of Medicine, Dartmouth-Hitchcock Medical Center, Hanover, New Hampshire**

1983-1985 **Resident, Department of Medicine, Dartmouth-Hitchcock Medical Center, Hanover, New Hampshire**

1985-1986 **Chief Medical Resident, Department of Medicine, Dartmouth-Hitchcock Medical Center, Hanover, New Hampshire**

Fellowships:

1986-1987 **Clinical Fellow, Infectious Diseases, Department of Medicine, University of Colorado Health Sciences Center, Denver, Colorado**

1987-1990 **Research Fellow, Infectious Disease Unit, Department of Medicine,**

Massachusetts General Hospital, Harvard Medical School, Boston,
Massachusetts

ACADEMIC APPOINTMENTS

1991-Present	Associate Professor of Medicine, University of Alabama at Birmingham School of Medicine, Birmingham, Alabama
1991-Present	Associate Professor of Microbiology, University of Alabama at Birmingham School of Medicine, Birmingham, Alabama
1991-Present	Associate Scientist, Center for AIDS Research, University of Alabama at Birmingham, Birmingham, Alabama
1991-1997	Assistant Professor of Medicine, University of Alabama at Birmingham School of Medicine, Birmingham, Alabama
1991-1997	Assistant Professor of Microbiology, University of Alabama at Birmingham School of Medicine, Birmingham, Alabama
1990-1991	Instructor of Medicine, Harvard Medical School, Boston, Massachusetts
1987-1990	Research Fellow in Medicine, Harvard Medical School, Boston, Massachusetts
1986-1987	Clinical Fellow in Medicine, University of Colorado Health Sciences Center, Denver, Colorado
1985-1986	Instructor in Medicine, Dartmouth-Hitchcock Medical School, Hanover, New Hampshire

AWARDS/HONORS

1984	Humanistic Physician Award, Department of Medicine, Dartmouth-Hitchcock Medical Center, Hanover, New Hampshire
1985	Resident of the Year, Department of Medicine, Dartmouth-Hitchcock Medical Center, Hanover, New Hampshire

PROFESSIONAL SOCIETIES

1989-Present	American Society for Microbiology
1989-Present	International Society for Antiviral Research

1990-Present	Pan American Group for Rapid Viral Diagnosis
1990-Present	Fellow, Massachusetts Medical Society
1991-Present	Member, American College of Physicians
1991-Present	Fellow, Infectious Diseases Society of America
1991-Present	Member, American Association for the Advancement of Science
1992-Present	Member, American Federation for Clinical Research
1994-Present	Member, Southern Society for Clinical Investigation
1998-Present	Member, Jefferson County Medical Society (JCMS)
2000-Present	Member, Medical Association of the State of Alabama (MASA)
2000-Present	Member, Northern New England Infectious Disease Society

COUNCILS AND COMMITTEES

International:

1993	Scientific Committee Member, Second International Workshop on HIV Drug-Resistance, Noordwijk, The Netherlands, June 3-5
1994	Scientific Committee Member, Third International Workshop on HIV Drug-Resistance, Kauai, Hawaii, August 2-5
1995	Scientific Committee Member, Fourth International Workshop on HIV Drug-Resistance, Sardinia, Italy, July 6-9
1996	Scientific Committee Member, Fifth International HIV Drug-Resistance Workshop, Whistler, British Columbia, July 3-6
1996	Scientific Program Member, International Scientific Committee (Clinical Science), XI International Conference on AIDS, Vancouver, British Columbia, July 7-12
1997	Scientific Committee Member, International Workshop on HIV Drug Resistance, Treatment Strategies, and Eradication, St. Petersburg, Florida, June 25-28.
1997-Present	Protocol Virologist, An International Multicenter Randomized Open-Label Strategic Study to Evaluate the Safety and Efficacy of 3 Different Convergent and Divergent Drug Combination Therapies in Antiretroviral Naïve HIV-1 Infected Patients with CD4 + Counts Above 200/mm ³ (Atlantic Study)
1998-Present	Protocol Virologist, An International Multicenter Open-Label Strategic Study to Evaluate the Effect of "Salvage" Treatment for Patients who Fail on an Initial Antiretroviral Triple Drug Combination Therapy (Atlantic Study Plus)

- 1998 Scientific Committee Member, 2nd International Workshop on HIV Drug Resistance and Treatment Strategies, Lake Maggiore, Italy, June 24-27
- 1998 Scientific Program Member, International Scientific Committee(Clinical Science), XII International Conference on AIDS, Geneva, Switzerland, July 28-July 3
- 1998 Scientific Advisory Board Member, International Conference on the Discovery and Clinical Development of Antiretroviral Therapies, St.Thomas, West Indies, December 13-17
- 1999 Scientific Committee Member, 3rd International Workshop on HIV Drug Resistance and Treatment Strategies, San Diego, USA, June 23-26
- 2000 Scientific Committee Member, 4th International Workshop on HIV Drug Resistance and Treatment Strategies, Sitges, Spain, June 12-16
- 2001 Scientific Committee Member, 5th International Workshop on HIV Drug Resistance and Treatment Strategies, Scottsdale, Arizona, USA, June 4-8

National:

- 1990-Present Ad Hoc Consultant, Veterans Affairs Medical Research Merit Review, Virology Study Section
- 1990-1994 Member, NIH/NIAID Adult AIDS Clinical Trials Group, Virology Committee Resistance Working Group
- 1992-1994 Member, NIH/NIAID Adult AIDS Clinical Trials Group, Primary Infection Committee Combination Therapies Working Group
- 1992-1994 Vice-Chair, NIH/NIAID Adult AIDS Clinical Trials Group, Virology Committee Resistance Working Group
- 1993- Protocol Virologist, NIH/NIAID Adult AIDS Clinical Trials Group Protocol 241, A Multicenter Comparative Study of a Combination of Zidovudine, Didanosine, and Double-Blinded Nevirapine versus a Combination of Zidovudine and Didanosine
- 1993- Protocol Virologist, NIH/NIAID Adult AIDS Clinical Trials Group Protocol 259, A Multicenter Phase II Double-Blind Study of Two Doses of SC-49483 in Combination with Zidovudine (ZDV) versus ZDV

1994-1996	Member, NIH/NIAID Adult AIDS Clinical Trials Group, Joint Adult and Pediatric Virology Core Committee
1994-1998	Permanent Member, NIH/NIAID AIDS and Related Research Grant Study Section, ARRD (Experimental Therapeutics)
1994-1996	Member, NIH/NIAID Adult AIDS Clinical Trials Group, Virology Assay Development Committee
1994-Present	Co-Chair, NIH/NIAID Adult AIDS Clinical Trials Group, Viral Resistance Phenotypic Screening Assay Committee
1994-Present	Vice-Chair and Protocol Virologist, NIH/NIAID Adult AIDS Clinical Trials Group Protocol 276, A Multicenter Phase II Double-Blind Study of the Differences Among Various Antiretroviral Therapies on Quantitative Measures of Viral Burden in Relatively Early HIV-1 Infection (CD4 + T lymphocytes \geq 550 cells/mm ³)
1995-Present	Member, NIH/NIAID Adult AIDS Clinical Trials Group, Viral Resistance Genotypic Committee
1995-Present	Protocol Vice-Chair, NIH/NIAID Adult AIDS Clinical Trials Group Protocol 306, A Phase II Randomized Study of the Antiviral and Resistance Interactions of Lamivudine (3TC) in Combination with Zidovudine (ZDV), Stavudine (d4T), or Didanosine (ddI) versus Monotherapy with ddI or d4T in HIV-infected Individuals with 200-600 CD4 + cells/mm ³ and No Previous Nucleoside Experience
1996-1998	Permanent Member, NIH/NIAID Microbiologic and Immunologic Sciences Special Emphasis Study Section Panel (Small Business Innovation Research)
1996-Present	NIH/NIAID Virology Branch/Enteric Diseases Branch/Collaborative Antiviral Study Group (CASG) Ad Hoc Viral Hepatitis Working Group
1996-Present	Invited Member, Hepatitis Subcommittee for the NIH/NIAIDS Collaborative Antiviral Study Group
1997-Present	Elected Member, NIH/NIAID Adult AIDS Clinical Trials Group HIV Disease Research Advisory Committee (RAC)
1997-Present	Protocol Vice Chair, NIH/NIAID Adult AIDS Clinical Trials Group Protocol 370, A Study of the Virologic and Immunologic Activity of Continued Lamivudine (3TC™) Versus Delavirdine (DLV) in Combination with Indinavir (IDV) and Zidovudine (2DV) or Stavudine (d4T) in 3TC™ Experienced Subjects

1997-Present	Protocol Virologist, NIH/NIAID Adult AIDS Clinical Trials Group/ Collaborative Antiviral Study Group Protocol A5075 in Development, A Collaborative, Multicenter, Double-Blind Placebo-Controlled Phase I/II Trial of Adefovir and Lamivudine Compared with Lamivudine Alone for the Treatment of Chronic Hepatitis B Virus Infection
1997-Present	Protocol Virologist, NIH/NIAID Adult AIDS Clinical Trials Group Protocol 891, A Study of the Impact of Intercurrent Illness on HIV Viral Load
1997-Present	Protocol Virologist, The Atlantic Study: a randomized, open-label trial comparing two protease inhibitor (PI)-sparing antiretroviral strategies versus a standard PI-containing regimen, 48 week data (International Investigator-initiated).
1998-Present	Protocol Virologist, A Randomized Placebo-Controlled Study of the Safety and Efficacy of Efavirenz, Didanosine and Stavudine in Combination With or Without Hydroxyurea in Antiretroviral Naïve or Experienced HIV-Infected Patients (International Investigator-initiated 3D Study)
1998-Present	Protocol Co-Virologist, NIH/NIAID Adult AIDS Clinical Trials Group Protocol 384, A Study of Protease Inhibitors and/or Non-Nucleoside Reverse Transcriptase Inhibitor with Dual Nucleosides in Initial Therapy of HIV Infection
1998-Present	Protocol Virologist, NIH/NIAID Adult AIDS Clinical Trials Group Protocol A5024, A Study of Combination of HAART and Immune Activation to Clear Latent HIV Infection
1998-2001	Invited Member, Infectious Diseases Society of America Fellowship & Young Investigator Grants Award Committee
2000-Present	Protocol Virologist, NIH/NIAID Adult AIDS Clinical Trials Group Protocol A5127, A Randomized, Controlled Trial Comparing the Efficacy of Adefovir Dipivoxil and Tenofovir Disoproxil Fumarate for The Treatment of Lamivudine-Resistant Hepatitis B Virus (HBV) in Subjects who are Co-Infected with HIV
2001-Present	Protocol Virologist, A Phase II/III Study of Adefovir Dipivoxil, Pegylated Interferon Alfa-2A, and Ribavirin Treatment in HBV and HCV-Infected Subjects with HIV Disease

- 2001-Present Ad Hoc Study Section Member, NIH/NIAID AIDS and Related Research Grant Study Section, AARR3 (Experimental Therapeutics and Special Emphasis Panel)
- 2001 Invited Guest Consultant, Food and Drug Administration (FDA) Center for Drug Evaluation and Research Antiviral Drug Advisory Committee (ADAC) Meeting for New Drug Applications for Treatment of HIV-1 Infection (Tenofovir), Silver Spring, MD, October 3
- 2002 Invited Member, Food and Drug Administration (FDA) Center for Drug Evaluation and Research Antiviral Drug Advisory Committee Meeting (ADAC) for New Drug Applications for Treatment of HIV-1 Infection

Local:

- 1991-Present Vice-Chair, Biohazard/Chemical Safety Subcommittee, Veterans Affairs Medical Center Birmingham
- 1992-Present Internal Scientific Review Committee Meeting, Center for AIDS Research, Developmental Awards
- 1993-Present Veterans Affairs Medical Center/Research and Development Oncology "A" Subcommittee
- 1995-Present Co-Director, Clinical and Molecular Virology Core, University of Alabama at Birmingham Liver Center
- 1997-Present Mentor, UAB Department of Medicine Women in Medicine Group
- 1997-1999 Mentor, UAB Medical Student Mentor Program
- 1998-2000 Elected Alternate Senator, UAB Faculty Senate
- 1998-2000 Member, UAB Faculty Senate Curriculum and Research Committee
- 1998-Present Invited Member, UAB Department of Medicine Research Development Group
- 1998-Present Invited Alternate Member, UAB Department of Medicine Intern Selection Committee
- 1998-Present Invited Member, UAB Department of Medicine Faculty Mentoring Program
- 2000-Present Invited Alternate Member, UAB Institutional Review Board (IRB)

For Human Use

2002-Present Department of Medicine's Women's Committee

UNIVERSITY ACTIVITIES

Teaching Experience:

1985-1986	Attending Physician, Department of Medicine, Dartmouth-Hitchcock Medical Center, Hanover, New Hampshire
1985-1986	Attending Physician, Medical Service, White River Junction Veterans Affairs Hospital, White River Junction, Vermont
1990-1991	Attending Physician, Massachusetts General Hospital, Boston (fellows, residents, medical students)
1990-1991	Supervisor of Post-Graduate Fellows in Virology Laboratory Research, Massachusetts General Hospital, Boston
1990-1991	Organizer and Lecturer, Infectious Diseases Unit, Massachusetts General Hospital, Virology Research Lecture Series
1991	Lecturer, Harvard Medical School and Massachusetts General Hospital Postgraduate Courses in Infectious Diseases and Pulmonary Medicine
1991-Present	Attending Physician, Department of Medicine, University of Alabama at Birmingham
1991-Present	Staff Physician, Medical Service Infectious Diseases, Department of Veterans Affairs Medical Center, Birmingham, Alabama
1991-Present	Preceptor, HIV (1917) Outpatient Clinic, Department of Medicine, University of Alabama at Birmingham
1991-Present	Preceptor, ID Special (HIV) Outpatient Clinic, Medical Service, Birmingham Veterans Affairs Medical Service
1991	Lecturer, UAB Research Center in Oral Biology Seminar Series
1992-Present	Teaching Faculty, Microbiology Course for Second Year Medical Students, University of Alabama at Birmingham Medical School

1993-Present Supervisor of Post-Graduate Fellows in Infectious Diseases and Virology Laboratory Research, Division of Infectious Diseases, Department of Medicine, University of Alabama at Birmingham School of Medicine

EDITORIAL BOARD MEMBERSHIPS

Reviewer, The New England Journal of Medicine
Reviewer, Annals of Internal Medicine
Reviewer, American Journal of Medicine
Reviewer, Antimicrobial Agents and Chemotherapy
Reviewer, Clinical Infectious Diseases
Reviewer, Journal of Infectious Diseases
Reviewer, Journal of Acquired Immunodeficiency Syndromes and Human Retrovirology
Reviewer, American Journal of the Medical Sciences
Reviewer, Antiviral Research
Reviewer, AIDS Research and Human Retroviruses
Reviewer, The Journal of Clinical Investigation
Reviewer, Journal of Virology

MAJOR LECTURES AND VISITING PROFESSORSHIPS

1996 Plenary Speaker, Frontiers for Antimicrobial Susceptibility Testing: Where Procedures Meet Reality, "What is the Clinical Role of Measurement of Drug Resistance in HIV-1 Infections?", 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, Infectious Diseases Society of America 34th Annual Meeting, New Orleans, Louisiana, October 18

1996 Plenary Speaker, Progress in Antiretroviral Chemotherapy, "Resistance to Antiretroviral Chemotherapeutic Agents", Infectious Diseases Society of America, New Orleans, Louisiana, October 20

GRANT SUPPORT

Past:

1988-1990 Principal Investigator, Individual National Research Service Award, (NRSA) National Institutes of Health (National Institute of Allergy and Infectious Diseases, Virology #F32-7933)
Title: Antiviral Drug Combinations in HIV Infections
Total Direct Cost: \$59,500
Project Period: 7/1/88-7/1/90

1991-1996	<p>Principal Investigator, First Award, National Institutes of Health (National Institute of Allergy and Infectious Diseases, Virology 1 R29 31857 ARRD)</p> <p>Title: Breakthrough of HIV-1 Replication During Drug Therapy</p> <p>Total Direct Cost: \$350,000</p> <p>Project Period: 9/1/91-5/31/96</p>
1992-1996	<p>Principal Investigator, Developmental Virology Research Award (C.3) for UAB Adult Clinical Trials Unit, National Institutes of Health (National Institute of Allergy and Infectious Diseases, U01 32775)</p> <p>Title: ACTG C.3 Developmental Virology Research</p> <p>Total Direct Cost: \$381,609</p> <p>Project Period: 4/1/92-1/31/96</p>
1996 -1999	<p>Co-Investigator, National Institutes of Health (National Institute of Allergy and Infectious Diseases, NIH AI-32775-07)</p> <p>Title: Adult AIDS Clinical Trials: UAB/Emory/ACTU</p> <p>Total Direct Cost: \$6,638,964</p> <p>Project Period: 1/1/96-12/31/99</p>
1996-1997	<p>Co-Principal Investigator, Advanced Technology Laboratory for UAB Adult Clinical Trials Unit, National Institutes of Health (National Institute of Allergy and Infectious Diseases, NIH AI-95-A02)</p> <p>Title: ACTG Virology Advanced Technology Laboratory</p> <p>Total Direct Cost: \$976,687</p> <p>Project Period: 1/1/96-12/31/97</p>
1997 - 1999	<p>Co-Investigator, National Institutes of Health (National Institute of Allergy and Infectious Diseases AI-41089), AIDS Clinical Trials Group</p> <p>Title: Pediatric AIDS Clinical Trials Group Virology Core Laboratory</p> <p>Total Direct Cost: \$700,666</p> <p>Project Period: 3/1/97-2/28/01</p>
1997 - 1999	<p>Co-Investigator, UAB Health Services Foundation General Endowment Fund</p> <p>Title: Liver Center Database/ Clinical Specimen Repository/ Virology Laboratory</p> <p>Total Direct Cost: </p> <p>Project Period: 2/1/97-1/31/99</p>
1998 - 1999	<p>Principal Investigator, National Institutes of Health (National Institute of Allergy and Infectious Diseases, NIH AI-95-A02), AIDS Clinical Trials Group</p> <p>Title: ACTG Virology Advanced Technology Laboratory</p>

for National Adult Clinical Trials Units
For
Total Direct Cost: \$976,687
Project Period: 1/1/96-12/31/99

1997 - 2000 Co-Investigator, Independent R01 Research Grant, National Institutes of Health (National Institute of Allergy and Infectious Diseases AI-33239)

Title: Mechanisms of Nucleoside Induced Toxicity and Activity
Total Direct Cost: \$905,534
Project Period: 4/1/97-6/30/01

1998 - 1999 Principal Investigator, National Institutes of Health (National Institute of Allergy and Infectious Diseases A200VC001), AIDS Clinical Trials Group

Title: ACTG Adult Virology Support Laboratory for National Adult Clinical Trials Units
Total Direct Cost: \$976,687
Project Period: 1/1/96-12/31/99

1999 - 2001 Principal Investigator, UAB Health Services Foundation General Endowment Fund

Title: Liver Center Molecular Virology Laboratory/Translational Research Laboratory
Total Direct Cost:
Project Period: 3/1/99-2/28/01

Current:

1996 - Principal Investigator, Independent R01 Research Grant, National Institutes of Health (National Institute of Allergy and Infectious Diseases, Virology, NIH AI-40876A-02)

Title: Sustained HIV-1 Suppression Despite Drug Resistance
Total Direct Cost: \$875,808
Project Period: 12/1/96-11/30/01

1997 - Co-Investigator, National Institutes of Health (National Institute of Allergy and Infectious Diseases AI-41530)

Title: HIV Acute Infection & Early Disease Research Unit
Total Direct Cost: \$3,004,451
Project Period: 05/01/97-04/30/01

- 1998 - Co-Investigator, Center for AIDS Research, National Institutes of Health (National Institute of Allergy and Infectious Diseases)
Title: Center for AIDS Research (CFAR)
Total Direct Cost: \$5,372,905
Project Period: 3/30/88-2/28/03
- 1998 - Co-Investigator, Center for AIDS Research, National Institutes of Health (National Institute of Allergy and Infectious Diseases) DNA Sequencing Core
Title: Center for AIDS Research (CFAR) DNA Sequencing Core
Total Direct Cost: \$514,984
Project Period: 3/30/88-2/28/03
- 2000 - Co-Investigator, National Institutes of Health (National Institute of Allergy and Infectious Diseases, NIH AI-32775), AIDS Clinical Trials Group
Title: Adult AIDS Clinical Trials: UAB/Emory/ACTU
Total Direct Cost: \$9,810,127
Project Period: 1/1/00-12/31/04
- 2000- Principal Investigator, Veterans Affairs Merit Review
Title: Drug Resistance in Genital Tract Viruses From HIV-infected Women
Total Direct Cost:
Project Period: 4/1/00-3/31/03
- 2000- Co-Investigator, Independent RO1 Research Grant, National Institutes of Health (National Institute of Allergy and Infectious Diseases AI-45403)
Title: Promoting Adherence to Antiretroviral Regimens
Total Direct Cost: \$1,791,000
Project Period: 9/01/00-7/13/04

BIBLIOGRAPHY

Manuscripts:

1. Fisher RA, Bertonis JM, Meier W, Johnson VA, Costopoulos DS, Liu T, Tizard R, Walker BD, Hirsch MS, Schooley RT, Flavell RA. HIV infection is blocked in vitro by recombinant soluble CD4. Nature 1988;331:76-8.
2. Johnson VA, Walker BD, Barlow MA, Paradis TJ, Chou T-C, Hirsch MS. Synergistic inhibition of human immunodeficiency virus type 1 and type 2 replication in vitro by

- castanospermine and 3'-azido-3'-deoxythymidine. Antimicrob Agents Chemother 1989;33:53-7.
3. Johnson VA, Barlow MA, Chou T-C, Fisher RA, Walker BD, Hirsch MS, Schooley RT. Synergistic inhibition of human immunodeficiency virus type 1 (HIV-1) replication in vitro by recombinant soluble CD4 and 3'-azido-3'-deoxythymidine. J Infect Dis 1989;159:837-44.
 4. Johnson VA, Barlow MA, Merrill DP, Chou T-C, Hirsch MS. Three drug synergistic inhibition of HIV-1 replication in vitro by zidovudine, recombinant soluble CD4, and recombinant interferon alpha-A. J Infect Dis 1990;161:1059-67.
 5. Johnson VA, Merrill DP, Videler JA, Chou T-C, Byington RE, Eron JJ, D'Aquila RT, Hirsch MS. Two drug combinations of zidovudine, didanosine, and recombinant interferon-alpha-A inhibit replication of zidovudine-resistant HIV-1 synergistically in vitro. J Infect Dis 1991;164:646-55.
 6. Eron JJ, Johnson VA, Merrill DP, Chou T-C, Hirsch MS. Synergistic inhibition of replication of HIV-1, including a zidovudine-resistant isolate, by the combination of zidovudine and 2',3'-dideoxycytidine in vitro. Antimicrob Agents Chemother 1992;36:1559-62.
 7. Johnson VA, Merrill DP, Chou T-C, Hirsch MS. HIV-1 inhibitory interactions between protease inhibitor Ro 31-8959 and either zidovudine, dideoxycytidine, or recombinant interferon-alpha-A against zidovudine-sensitive or -resistant HIV-1 in vitro. J Infect Dis 1992;166:1143-6.
 8. Japour AJ, Mayers DL, Johnson VA, Kuritzkes DR, Beckett LA, Arduino JM, Lane J, Black RJ, Reichelderfer PS, D'Aquila RT, Crumpacker CS, RV-43 Study Group, and the AIDS Clinical Trials Group Virology Committee Resistance Working Group. Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. Antimicrob Agents Chemother 1993;37:1095-101.
 9. Johnson VA. Combination Therapy: more effective control of HIV type 1? AIDS Research and Human Retroviruses 1994;10:907-12.
 10. Johnson VA. Nucleoside RT inhibitors and HIV resistance. J Infect Dis 1995;171:140-9.
 11. Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA, Deutsch P, Lifson JD, Bonhoeffer S, Nowak MA, Hahn BH, Saag MS, Shaw GM. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995;373:117-22.
 12. D'Aquila RT, Johnson VA, Welles SL, Japour AJ, Kuritzkes DR, DeGruttola V, Reichelderfer PS, Coombs RW, Crumpacker CS, Kahn JO, and Richman DD for the

- AIDS Clinical Trials Group Protocol 116B/117 Team and the Virology Committee Resistance Working Group. Zidovudine resistance and human immunodeficiency virus type 1 disease progression during antiretroviral therapy. Ann Intern Med 1995;122:401-8.
13. Japour AJ, Welles S, D'Aquila RT, Johnson VA, Richman DD, Coombs RW, Reichelderfer PS, Kahn JO, Crumpacker CS, and Kuritzkes DR for the ACTG Clinical Trials Group 116B/117 Study Team and the Virology Committee Resistance Working Group. Prevalence and clinical significance of zidovudine resistance mutations in human immunodeficiency virus isolated from patients after long-term zidovudine treatment. J Infect Dis 1995;171:1172-9.
 14. Johnson VA. Combination therapy for HIV-1 infection - overview: preclinical and clinical analysis of antiretroviral combinations. Antiviral Research 1996;29:35-9.
 15. D'Aquila RT, Hughes MD, Johnson VA, Fischl MA, Sommadossi J-P, Liou S-H, Timpone J, Myers M, Basgoz N, Niu M, Hirsch MS, and the National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators. Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1996;124:1019-30.
 16. Bartlett JA, Benoit SL, Johnson VA, Quinn JB, Sepulveda GE, Ehmann WC, Tsoukas C, Fallon MA, Self PL, Rubin M and the North American HIV Working Party. Lamivudine plus zidovudine compared with zalcitabine plus zidovudine in patients with HIV infection. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1996;125:161-72.
 17. Welles SL, Jackson JB, Yen-Lieberman B, Demeter L, Japour AJ, Smeaton LM, Johnson VA, Kuritzkes DR, D'Aquila RT, Reichelderfer PA, Richman DD, Reichman R, Fischl M, Dolin R, Coombs RW, Kahn JO, McLaren C, Todd J, Kwok S, and Crumpacker CS, for the AIDS Clinical Trials Group Protocol 116A/116B/117 Team. Prognostic value of plasma human immunodeficiency virus type 1 (HIV-1) RNA levels in patients with advanced HIV-1 disease and with little or no prior zidovudine therapy. J Infect Dis 1996;174:696-703.
 18. Coombs RW, Welles SL, Hooper C, Reichelderfer PS, D'Aquila RT, Japour AJ, Johnson VA, Kuritzkes DR, Richman DD, Kwok S, Todd J, Jackson JB, DeGruttola V, Crumpacker CS, and Kahn J for the AIDS Clinical Trials Group (ACTG) 116B/117 Study Team and the ACTG Virology Committee Resistance and HIV-1 RNA Working Groups. Association of plasma human immunodeficiency virus type-1 RNA level with risk of clinical progression in patients with advanced infection. J Infect Dis 1996;174:704-12.
 19. Marschner IC, Mayers DL, Erice A, Smeaton L, Johnson VA, Richman DD, Reichelderfer P, Japour AJ. Standardized peripheral blood mononuclear cell culture

- assay for zidovudine susceptibility testing of clinical HIV-1 isolates: effect of reducing the number of replicates and concentrations. J Clin Microb 1997;35:756-8.
20. Hughes MD, Johnson VA, Hirsch MS, Bremer JW, Elbeik T, Erice A, Kuritzkes DR, Scott WA, Spector SA, Basgoz N, Fischl MA, D'Aquila RT for the ACTG 241 Protocol Virology Substudy Team. Monitoring plasma HIV-1 RNA levels in addition to CD4 + lymphocyte count improves assessment of antiretroviral therapeutic response. Ann Intern Med 1997;126:929-38
 21. Phillips AN, Eron J, Bartlett J, Kuritzkes DR, Johnson VA, Gilbert C, Johnson J, Keller A, Hill AM and the North American Lamivudine HIV Working Group. Correspondence between the effect of zidovudine plus lamivudine on plasma HIV level/CD4 lymphocyte count and the incidence of clinical disease in infected individuals. AIDS 1997;11:169-75.
 22. Marschner IC, Collier AC, Coombs RW, D'Aquila RT, DeGruttola V, Fischl MA, Hammer SM, Hughes MD, Johnson VA, Katzenstein DA, Richman DD, Smeaton LM, Spector SA, Saag MS. Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy. J Infect Dis 1998;177:40-7.
 23. D'Aquila RT, Sutton L, Savara A, Hughes MD, Johnson VA for the NIAID AIDS Clinical Trial Group Protocol 241 Virology Team. CCR5/ Δ ccr5 heterozygosity: a selective pressure for the syncytium-inducing HIV-1 phenotype. J Infect Dis 1998;177:1549-53.
 24. Hirsch MS, Conway B, D'Aquila RT, Johnson VA, Brun-Vézinet F, Clotet B, Demeter LM, Hammer SM, Jacobsen DM, Kuritzkes DR, Loveday C, Mellors JW, Vella S, and Richman DD. Antiretroviral drug resistance testing in HIV infection: implications for clinical management. JAMA 1998;279:1984-91.
 25. Johnson VA. HIV resistance to antiretroviral drugs. In: Richman DD, ed. Improving the Management of HIV Disease. San Francisco: International AIDS Society USA. 1998;6(2):8-.
 26. Demeter LM, D'Aquila RT, Weislow O, Lorenzo E, Erice A, Fitzgibbon J, Shafer R, Richman D, Howard TM, Zhao Y, Fisher E, Huang D, Mayers D, Sylvester S, Arens M, Sannerud K, Rasheed S, Johnson V, Kuritzkes D, Reichelderfer P, Japour A, for the ACTG Sequencing Working Group. Interlaboratory concordance of DNA sequence analysis to detect reverse transcriptase mutations in HIV-1 proviral DNA. J Virol Methods 1998;75:93-104.
 27. Zhou X-J, Sheiner LB, D'Aquila RT, Hughes MD, Hirsch MS, Fischl MA, Johnson VA, Myers M, Sommadossi J-P, and the National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators. Population

pharmacokinetics of nevirapine, zidovudine and didanosine in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 1999;43:121-8.

28. Kuritzkes DR, Marschner I, Johnson VA, Bassett R, Eron JJ, Fischl MA, Murphy RL, Fife K, Maenza J, Rosandich ME, Bell D, Wood K, Sommadossi J-P, Pettinelli C, and the National Institute of Allergy and Infectious Disease AIDS Clinical Trials Group Protocol 306 Investigators. Lamivudine in combination with zidovudine, stavudine, or didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. AIDS 1999;13:685-94.
29. Gunthard HF, Leigh-Brown A, D'Aquila RT, Johnson VA, Kuritzkes D, Richman DD, Wong JK. Higher selection pressure from antiretroviral drugs in vivo results in increased evolutionary distance in HIV-1 *pol* independent of mutations associated with drug resistance. Virology 1999;259:154-65.
30. Fiscus SA, Adimora AA, Schoenbach VJ, McKinney R, Lim W, Rupar D, Kenny J, Woods C, Wilfert C, Johnson VA. Trends in HIV counseling, testing, and antiretroviral treatment of human immunodeficiency virus-infected women and perinatal transmission in North Carolina. J Infect Dis 1999;180:99-105.
31. Leigh Brown AJ, Gunthard HR, Wong JK, D'Aquila RT, Johnson VA, Kuritzkes DR, Richman DD. Sequence clusters in human immunodeficiency virus type 1 reverse transcriptase are associated with subsequent virological response to antiretroviral therapy. J Infect Dis 1999;180:1043-9.
32. D'Aquila RT, Hughes M, Johnson VA. HIV-1 entry inhibitors and virus emergence (letter to the editor). Nature Medicine 1999;5:1091.
33. Precious HM, Gunthard HF, Wong JK, D'Aquila RT, Johnson VA, Kuritzkes DR, Richman DD, Leigh Brown AJ. Multiple sites in HIV-1 reverse transcriptase associated with virological response to combination therapy. AIDS 2000;14:31-6.
34. Sha BE, Johnson VA, Kendall MA, Hammerich R, Nokta M, Lamb K, Zackin RA, Nail CD, Currier JS. Absence of virologic changes following acute febrile illnesses in two patients with undetectable pre-illness plasma HIV-1 RNA levels. AIDS 2000;14:746-8.
35. Hanna GJ, Johnson VA, Kuritzkes DR, Richman DD, Leigh Brown AJ, Sutton L, Savara AV, Hazelwood JD, D'Aquila RT. Patterns of resistance mutations selected by treatment of human immunodeficiency virus type 1 infection with zidovudine, didanosine, and nevirapine. J Infect Dis 2000;181:904-911.
36. Hirsch MS, Brun-Vezinet F, D'Aquila RT, Hammer SM, Johnson VA, Kuritzkes DR, Loveday C, Mellors JW, Clotet B, Conway B, Demeter LM, Vella S, Jacobsen DM, Richman DD. Antiretroviral drug resistance testing in adult HIV-1 infection:

recommendations of an International AIDS Society-USA panel. JAMA 2000;283:2417-26.

37. Kuritzkes DR, Bassett RL, Johnson VA, Pettinelli CB, Marschner IC, Eron JJ, Sommadossi J-P for the Adult AIDS Clinical Trials Group 370 Protocol Team. Continued lamivudine vs delavirdine in combination with indinavir and zidovudine or stavudine in lamivudine-experienced patients. AIDS 2000;14:1553-61.
38. Gilbert PB, Hanna GJ, DeGruttola V, Martinez-Picado J, Kuritzkes DR, Johnson VA, Richman DD, D'Aquila RT. Comparative analysis of HIV-1 genotypic resistance across antiretroviral treatment regimens. AIDS Res. Human Retroviruses 2000;16:325-36.
39. Hanna GJ, Johnson VA, Kuritzkes DR, Richman DD, Martinez-Picado J, Leigh Brown AJ, Sutton L, Savara AV, Hazelwood JD, D'Aquila RT. Comparison of sequencing by hybridization and cycle sequencing for genotyping of human immunodeficiency virus type 1 reverse transcriptase. J Clin Microb 2000; 38:2715-21.
40. Call SA, Saag MS, Westfall AO, Raper JL, Pham SV, Tolson JM, Hellmann NS, Cloud GA, Johnson VA. Phenotypic drug susceptibility testing predicts long-term virologic suppression better than treatment history in human immunodeficiency virus-infected patients. J Infect Dis 2001;183:401-8.
41. D'Aquila RT, Shapiro JM, Brun-Vezinet FB, Clotet B, Conway B, Demeter LM, Johnson VA, Kuritzkes DR, Loveday C, Richman DD. Update on drug resistance mutations. Topics in HIV Medicine 2001; 9:31-33.
42. Johnson VA, Petropoulos CJ, Woods CR, Hazelwood JD, Parkin NT, Hamilton CD, Fiscus SA. Vertical transmission of multi-drug resistant human immunodeficiency virus type-1 (HIV-1) and continued evolution of drug resistance in an HIV-1-infected infant. J Infect Dis 2001;183:1688-93.
43. Coughlan ME, Sommadossi J-P, Jhala NC, Many WJ, Saag MS, Johnson VA. Symptomatic lactic acidosis in antiretroviral-treated HIV-infected patients. Clin Infect Dis 2001;33:1914-21.

Manuscript in press:

44. D'Aquila RT, Schapiro MJ, Brun-Vezinet F, Clotet B, Conway Demeter LM, Grant RM, Johnson VA, Kuritzkes DR, Loveday C, Shafer RW, Richman DD. Drug resistance mutations in HIV-1. Topics in HIV Medicine 2002.

Manuscripts submitted but not yet accepted:

45. Fischl MA, Stanley K, Saag MS, Johnson VA, Sommadossi J-P, Bassett R, Frame P, Dobkin JF, Hirschtick R, Powderly WG, Smith SL, and the ACTG 259 Team. A

phase II randomized, double-blind study of two doses of SC-49483, an HIV-1 alpha glucosidase I inhibitor, in combination with zidovudine (ZDV) versus ZDV (in revision).

46. Johnson VA, Quinn JB, Benoit SL, Hazelwood JD, Wagner SF, Overbay CB, Wagner JR, Fallon MA, Bartlett JA, Cammack N, Rubin M, and the North American HIV Working Party. Drug resistance and viral load in NUCA 3002: lamivudine plus zidovudine versus zalcitabine plus zidovudine in zidovudine-experienced HIV-infected subjects (in revision).
47. Demeter LM, Bosch RJ, Coombs RW, Fiscus S, Bremer J, Johnson V, Erice A, Jackson BJ, Spector SA, Squires KM, Fischl MA, Hughes MD, Hammer SM. Detection of replication-competent HIV-1 in cultures from patients with suppression of plasma HIV-1 RNA to less than 50 copies/mL (AIDS Clinical Trials Group [ACTG] Protocol 867)(submitted).
48. Murphy RL, Katlama C, Johnson VA, Squires K, Horban A, Gatell JM, Clotet B, Staszewski S, Van Leeuwen R, Clumeck N, Moroni M, Pavia AT, Schmidt SE, Gonzalez-Lahoz J, Antunes F, Gulick R, Banhegyi D, Montaner JSG, Sommadossi JP, Lange J. The Atlantic Study: a randomized, open-label trial comparing two protease inhibitor (PI)-sparing antiretroviral strategies versus a standard PI-containing regimen, 48 week data (in revision).
49. Ickovics JR, Cameron A, Zackin R, Bassett R, Chesney M, Johnson VA, Kuritzkes DR for the ACTG 370 Protocol Team. Consequences and Determinants of Adherence: Results from Adult AIDS Clinical Trials Group Protocol 370 (submitted)

Manuscripts in Preparation:

50. Johnson VA, Stanley K, Bassett R, Saag MS, Fischl MA. Frequency and virologic correlates of SI phenotype in ACTG 259: a phase II double-blind study of two doses of SC-49483 in combination with zidovudine (ZDV) versus ZDV (manuscript in preparation).
51. Hazelwood JD, Overbay CB, Koel JL, Nail CD, Bartlett JA, Quinn JB, Johnson J, Keller AL, Rubin M, Johnson VA. Drug resistance, viral load, and SI phenotype in NUCA 3002: combined 3TC/ZDV therapy over a maximum of 52 weeks in ZDV-experienced (≥ 24 weeks) patients ($CD4^+ 100-300$ cells/mm³) (manuscript in preparation).
52. Johnson VA, Stanley K, Bassett R, Saag MS. Phenotypic drug susceptibility testing of clinical HIV-1 isolates against SC-48334 in vitro (manuscript in preparation).
53. Johnson, VA, Patick AK, Kuritzkes D, Shugarts D, Bakhtiari M, Potts KE, Farnsworth A, Anderson R, Duran M, Markowitz M, Winters M, Merigan T, Ho D, and Richman D. Genotypic and phenotypic analyses of HIV-1 variants isolated from

patients treated with nelfinavir and other protease inhibitors (manuscript in preparation).

54. Eron JJ, St. Clair M, Gilbert C, Phillips AN, Keller A, Johnson J, Johnson VA. Rebound of plasma HIV-1 RNA after discontinuation of long-term 3TC/ZDV (manuscript in preparation).
55. Koel JL, Nail CD, Hazelwood JD, Marangos M, Smith R, Thompson M, Johnson VA. Multi-drug-resistant HIV-1 isolates from patients with rising plasma viral burden during double or triple combination therapy in clinical practice (manuscript in preparation).
56. Johnson VA, Hanna GJ, Kuritzkes DR, Richman DD, Leigh Brown AJ, Hazelwood JD, D'Aquila RT. Associations between virologic responses and resistance mutations selected by treatment of human immunodeficiency virus type 1 infection with zidovudine, didanosine, and nevirapine (manuscript in preparation).
57. Johnson VA, Koel JL, Rhodes RA, Hazelwood JD, Fiscus SA, Whitcomb JM, Parkin NT, Petropoulos CJ. Comparison of phenotypic and genotypic drug resistance testing results obtained by recombinant virus (plasma) and conventional culture-based (PBMC) methodologies using clinical HIV isolates (manuscript in preparation).
58. Johnson VA, Call SA, Westfall AO, Cloud GA, Acosta EP, Tolson JM, Larder BA, Saag MS. Predictive value of genotypic resistance testing as interpreted by experts and a virtual phenotype (manuscript in preparation).
59. Johnson VA, Bassett RL, Ickovics JR, Koel JL, Rhodes RA, Young RK, Barrett H, Hellmann NS, and Kuritzkes DR for the ACTG Protocol 370 Team. Selection of zidovudine (ZDV) resistance mutations by ZDV or stavudine (d4T)-based regimens, phenotypic correlates, medication adherence, and virological response (manuscript in preparation).
60. Hoesley C, Squires K, Nail C, Croom-Rivers A, Schwebke J, Johnson VA. Effect of bacterial vaginosis and/or vaginal trichomoniasis treatment on cervicovaginal HIV-1 shedding in HIV-1-seropositive women enrolled in an ongoing prospective natural history study at the University of Alabama at Birmingham Outpatient HIV Clinic (manuscript in preparation).
61. Johnson VA, Delaugerre C, Hazelwood J, Berzins B, Belsey E, Rhodes R, Calvez V, Katlama C, Murphy R for the International 3D Study Team. Viral resistance results from the international, multicenter, randomized, placebo-controlled, 48-week study of hydroxyurea (HU) or placebo combined with efavirenz (EFV), didanosine (ddI), and stavudine (d4T) in treatment naïve and experienced patients (manuscript in preparation).

BOOKS

Books and book chapters:

1. Johnson VA, Hirsch MS. Combination therapy for HIV infection. In: Mills J, Corey L, eds. Antiviral chemotherapy: new directions for clinical application and research. New York: Elsevier 1989;2:275-302.
2. Johnson VA, Hirsch MS. New developments in antiretroviral drug therapy for human immunodeficiency virus infections. In: Volberding P, Jacobson MA, eds. AIDS Clinical Review 1990. New York: Marcel Dekker, Inc. 1990; pp. 235-72.
3. Johnson VA, Hirsch MS. New developments in combination chemotherapy of anti-human immunodeficiency virus drugs. In: Georgiev VS, McGowan JJ, eds. AIDS: Anti-HIV agents, therapies, and vaccines. New York: Annals of the New York Academy of Science 1990; 16:318-55.
4. Johnson VA, Byington RE. Quantitative assays for virus infectivity. In: Aldovini A, Walker BD, eds. Techniques in HIV Research. Chapter 4. New York: Stockton Press 1990; pp. 71-6.
5. Johnson VA, Byington RE, Walker BD, Kaplan JC. Quantitative assays for virus detection. In: Aldovini A, Walker BD, eds. Techniques in HIV Research. Chapter 5. New York: Stockton Press 1990; pp. 87-102.
6. Johnson VA. Evaluation of candidate anti-HIV agents in vitro. In: Aldovini A, Walker BD, eds. Techniques in HIV Research. Chapter 13. New York: Stockton Press 1990; pp. 225-37.
7. Johnson VA. New developments in antiretroviral drug therapy for human immunodeficiency virus infections. In: Volberding P, Jacobson MA, eds. AIDS Clinical Review 1992. New York: Marcel Dekker, Inc. 1992; pp. 69-104.
8. Richman DD, Johnson VA, Mayers DL, Shirasaka T, O'Brien MC, Mitsuya H. In vitro evaluation of experimental agents for anti-HIV activity. In: Strober W, Shevach E, eds. Current Protocols in Immunology. Chapter 12.9.1. New York: Green Publishing Associates and Wiley-Interscience 1993.
9. Johnson VA. New developments in antiretroviral drug therapy for HIV-1 infections. In: Volberding P, Jacobson MA, eds. AIDS Clinical Review 1995/1996. New York: Marcel Dekker, Inc. 1995; pp. 305-37.
10. Johnson VA. Abacavir (1592U89). In: Dolin R, Masur H, Saag MS, eds. AIDS Therapy 1999; pp. 106-16.
11. Johnson VA. Abacavir. In: Dolin R, Masur H, Saag MS, eds. AIDS Therapy 2001

(in preparation).

Published abstracts and poster exhibits:

1. Johnson VA, Walker BD, Paradis TJ, Barlow MA, Sodroski J, Chou T-C, Schooley RT, Hirsch MS. Synergistic inhibition of HIV-1 replication by castanospermine (CAS) and either zidovudine (AZT) or recombinant soluble CD4 (rsT4) (abstract #3618). Proceedings of the Fourth International Conference on AIDS, Stockholm, Sweden, June 12-16, 1988;2:171.
2. Johnson VA, Barlow MA, Walker BD, Chou T-C, Fisher RE, Schooley RT, Hirsch MS. Synergistic inhibition of HIV-1 replication by recombinant soluble CD4 (rsT4) and zidovudine (AZT) (abstract #1299). Proceedings of the Twenty-eighth Interscience Conference on Antimicrobial Agents and Chemotherapy, Los Angeles, California, October 23-26, 1988; 343.
3. Johnson VA, Barlow MA, Walker BD, Chou T-C, Fisher RE, Hirsch MS, Schooley RT. Synergistic inhibition of HIV-1 replication by recombinant soluble CD4 (rsT4) and either zidovudine (AZT) or castanospermine (CAS). Proceedings of the NIH AIDS National Cooperative Drug Discovery and Development Meeting, Oakland, California, October 30-November 2, 1988.
4. Johnson VA, Barlow MA, Chou T-C, Merrill DP, Hirsch MS. Three drug synergistic inhibition of HIV-1 replication by recombinant soluble CD4 (rsT4), zidovudine (AZT), and recombinant interferon-alpha-A (rIFN- α -A) (abstract #M.C.P.97). Proceedings of the Fifth International Conference on AIDS, Montreal, Canada, June 4-9, 1989;558.
5. Johnson VA, Merrill DP, Chou TC, Hirsch MS. Synergistic inhibition of HIV-1 replication by N-butyl deoxynojirimycin (N-butyl DNJ) and zidovudine (AZT) (abstract #504). Proceedings of the Twenty-ninth Interscience Conference on Antimicrobial Agents and Chemotherapy, Houston, Texas, September 17-20, 1989;185.
6. Johnson VA, Merrill DP, Hirsch MS. Combination therapy for HIV infection (abstract #29). Proceedings of the Second HIV/NY Academy of Sciences International Conference on Drug Research in Immunologic and Infectious Disease. Acquired Immune Deficiency Syndrome (AIDS). Arlington, Virginia, November 6-9, 1989.
7. Johnson VA, Merrill DP, Chou T-C, Hirsch MS. HIV-1 inhibitory interactions between 2', 3'-dideoxyinosine (ddI) and either zidovudine (AZT), recombinant soluble CD4 (rsCD4) or recombinant interferon-alpha-A (abstract #F.A.66). Proceedings of the Sixth International Conference on AIDS, San Francisco, California, June 20-24, 1990;106.
8. Johnson VA, Merrill DP, Videler JA, Chou T-C, Byington RE, Kaplan JC, D'Aquila RT, Hirsch MS. Inhibition of zidovudine-resistant HIV-1 isolates in vitro by 2-drug

- combination regimens. The First Univ. of Miami and UCSD Joint Symposium "HIV Disease: Pathogenesis and Therapy", Grenellefe, Florida, March 13-17, 1991. Journal of Acquired Immune Deficiency Syndromes 1991;4:354.
9. D'Aquila RT, Videler JA, Bechtel LB, Johnson VA, Merrill DP, Eron JJ, Kaplan JC, Hirsch MS. Specific PCR detection and DNA sequence analysis of the AZT-resistant RT genotype of HIV-1. The First Univ. of Miami and UCSD Joint Symposium "HIV Disease: Pathogenesis and Therapy", Grenellefe, Florida, March 13-17, 1991. Journal of Acquired Immune Deficiency Syndromes 1991;4:346.
 10. Eron JJ, Hirsch MS, Merrill DP, Chou T-C, Johnson VA. Synergistic inhibition of HIV-1 by the combination of zidovudine (AZT) and 2',3'-dideoxycytidine (ddC) in vitro (abstract #W.B.2110). Proceedings of the Seventh International Conference on AIDS, Florence, Italy, June 16-21, 1991.
 11. D'Aquila RT, Videler JA, Eron J, Johnson VA, Bechtel LB, Merrill DP, Gorczyca P, Kaplan JC, Hirsch MS. Plasma and PBMC derived HIV-1 isolates differ in RT genotype and AZT susceptibility (abstract #W.B.2084). Proceedings of the Seventh International Conference on AIDS, Florence, Italy, June 16-21, 1991.
 12. Johnson VA, Merrill DP, Chou TC, Roberts NA, Hirsch MS. Human immunodeficiency virus type 1 (HIV-1) inhibitory interactions between HIV-1 protease inhibitor (Ro 31-8959, Compound XVII) and either zidovudine (AZT), 2',3'-dideoxycytidine (ddC) or recombinant interferon-alpha-A (rIFN- α -A) using either AZT-sensitive or AZT-resistant HIV-1 in vitro (abstract #38). Proceedings of the Fourth Conference of the NIH National Cooperative Drug Discovery Groups for the Treatment of HIV Infection, San Diego, California, November 3-7, 1991.
 13. Johnson VA. Combination therapy for HIV-1 (abstract #T-12.1). Proceedings of the Fifth National Forum on AIDS, Hepatitis, and Other Blood-Borne Diseases, Atlanta, Georgia, March 29-April 1.
 14. Johnson VA, Richman DD, Mayers DL. Drug susceptibility testing of HIV-1 in vitro: an overview of phenotypic assays. Proceedings of the Second Workshop on Viral Resistance, Herndon, Virginia, May 13-15 1992.
 15. Japour AJ, Kuritzkes D, Johnson V, Mayers D, Beckett L, Black R, D'Aquila R, Crumpacker C, and the Viral Resistance Working Group of the AIDS Clinical Trials Group (ACTG), USA. Consensus protocol to measure antiviral resistance in clinical HIV-1 isolates (abstract #PoA 2484). Proceedings of the Eighth International Conference on AIDS/III STD World Congress, Amsterdam, the Netherlands, July 19-24, 1992.
 16. Johnson VA, Balfour H, Beckett L, Chesebro B, Crumpacker C, Haberzettl C, Japour A, Katzenstein D, Kuritzkes D, Mayers D, McIntosh K, Rangan S, Reichman R, Richman D, Smith W, D'Aquila R, and the AIDS Clinical Trials Group (ACTG)

- Virology Committee Virus Resistance Working Group, USA. Evaluation of inter-laboratory variability of anti-HIV-1 susceptibility testing (abstract #PoA 2310). Proceedings of the Eighth International Conference on AIDS/III STD World Congress, Amsterdam, the Netherlands, July 19-24, 1992.
17. Kuritzkes DR, Johnson VA, Crumpacker CS, Japour AJ, and the ACTG 116B/117 Virology Resistance Team. Baseline prevalence and clinical significance of zidovudine (ZDV) resistance mutations in HIV-1 isolates from patients participating in ACTG Protocol 116B/117. Proceedings of the Second International HIV Drug Resistance Workshop, Noordwijk, the Netherlands, June 3-5, 1993.
 18. Shafer R, Mayers D, Erice A, Kuritzkes D, Japour A, Johnson V, Reichelderfer P. Designing an AIDS Clinical Trial Group (ACTG) consensus protocol for detecting a mutation at codon 215 of HIV-1 (HIV) pol. Proceedings of the Second International Drug Resistance Workshop, Noordwijk, the Netherlands, June 3-5, 1993.
 19. D'Aquila R, Johnson V, Kuritzkes D, Japour A, Crumpacker C, Richman D, et al., for the NIH AIDS Clinical Trials Group (ACTG) Virology Committee Resistance Working Group and the ACTG Protocol 116B/117 Team. HIV-1 drug resistance and syncytium-inducing phenotype: associations with disease progression among ACTG 116B/117 subjects (abstract #PO-B26-2046). Proceedings of the Ninth International Conference on AIDS/IVth STD World Congress, Berlin, Germany, June 6-11, 1993.
 20. Havlir D, Murphy R, Saag M, Kaul I, Johnson V, Richman DD, and the ACTG 164 and 168 Study Teams. Nevirapine: further dose escalation of monotherapy (600 mg/daily) and combination therapy with zidovudine (abstract #268). Proceedings of the First National Conference on Human Retroviruses and Related Infections, Washington, D.C., December 12-16, 1993.
 21. Cavert W, Coombs RW, Grimes J, Kuritzkes D, Rojo E, Johnson V, Kappes J, Stein D, Beatty C, Erice A, Winters M, Katzenstein D, Staes B, Mirabile M, Elbeik T, Corey L and the ACTG Protocol 194 Clinics and Virology Laboratories. Baseline zidovudine (ZDV) susceptibility, codons 215 and 41 mutation genotype, viral load and syncytium-inducing characteristics of HIV isolates from ACTG protocol 194 subjects (abstract #JS05). Proceedings of the Keystone Symposia on Molecular and Cellular Biology, Keystone, Colorado, January 21-February 13, 1994.
 22. Johnson V, Saag M, Decker J, Sommadossi J-P, Myers M, Cort S, Hall D, Griffin J, Lifson J, Shaw G. Viral resistance in adults treated with nevirapine (NVP) added to established nucleoside RT inhibitor regimens of ZDV + ddC, ZDV + ddI, or ddI alone (abstract #70). Proceedings of the Third International HIV Drug Resistance Workshop, Kauai, Hawaii, August 2-5, 1994.
 23. Shaw G, Wei X, Johnson V, Taylor M, Decker J, Kilby M, Lifson J, Hahn B, Saag M. Nucleotide sequence analysis of HIV-1 RNA and DNA from plasma and PBMCs of patients treated with ZDV, ddI, and nevirapine: rapid HIV-1 turnover and

- resistance development in vivo (abstract #71). Proceedings of the Third International HIV Drug Resistance Workshop, Kauai, Hawaii, August 2-5, 1994.
24. Hooper C, Welles S, D'Aquila R, Japour A, Johnson V, Kuritzkes D, Jackson B, DeGruttola V, Crumpacker C, Richman D, Kahn J, Kwok S, Todd J, Reichelderfer P, and Coombs R for the ACTG Virology PCR Validation and Resistance Working Groups, ACTG 116B/117 Study Team. HIV-1 RNA level in plasma and association with disease progression, zidovudine sensitivity phenotype and genotype, syncytium-inducing phenotype, CD4 + cell count and clinical diagnosis of AIDS (abstract #67). Proceedings of the Third International HIV Drug Resistance Workshop, Kauai, Hawaii, August 2-5, 1994.
 25. Saag M, Johnson V, Wei X, Sommadossi J-P, Myers M, Cort S, Hall D, Piatak M, Lifson J, Shaw G, and the BIPI 1009 Working Group. Clinical, pharmacokinetic, and virologic results in adults treated with nevirapine (NVP) in combination with AZT/ddC, AZT/ddI, or ddI alone: final report of the BIPI 1009 study (abstract #M16). Proceedings of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, Orlando, Florida, October 4-7, 1994.
 26. Wei X, Johnson V, Taylor M, Decker J, Kilby M, Lifson J, Hahn B, Saag M, Shaw G. Rapid HIV-1 turnover in patients receiving combination Nevirapine (NVP) therapy (abstract #164). Proceedings of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, Orlando, Florida, October 4-7, 1994.
 27. Kilby M, Taylor M, Wei X, Johnson V, Lifson J, Hahn B, Saag M, Shaw G. In situ expression and functional analysis of HIV-1 reverse transcriptase (RT) in patients treated with nevirapine (NVP), AZT, and ddI (abstract #1216). Proceedings of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, Orlando, Florida, October 4-7, 1994.
 28. Welles SL, Jackson JB, Yen-Lieberman B, Demeter L, Japour AJ, Johnson VA, Kuritzkes DR, D'Aquila RA, Reichelderfer P, Richman DD, Crumpacker CS. Prognostic capacity of plasma HIV-1 RNA copy number in ACTG 116A (abstract #230). Proceedings of the Second National Conference on Human Retroviruses and Related Infections, Washington, D.C., January 29-February 2, 1995.
 29. Shaw G, Wei X, Ghosh S, Taylor M, Kilby Jr. JM, Johnson V, Emini E, Lifson J, Hahn B, Saag M. Viral dynamics in HIV-1 infection (abstract #19). Proceedings of the Second National Conference on Human Retroviruses and Related Infections, Washington, D.C., January 29-February 2, 1995.
 30. Johnson VA, Wagner SF, Overbay CB, Wagner JF, Cammack N, Penn CR, Rubin M, Bartlett JA, Fallon M, Quinn JB, Benoit SL. Drug resistance and viral load in NUCA 3002: a comparative trial of lamivudine (3TC) (high or low dose)/zidovudine (ZDV) combination therapy vs. ZDV/dideoxycytidine (ddC) combination therapy in ZDV-experienced (≥ 24 weeks) patients (CD4 cells 100-300/mm³) (abstract #55).

Proceedings of the Fourth International Workshop on HIV Drug-Resistance, Sardinia, Italy, July 6-9, 1995.

31. Havlir DV, Johnson VA, Hall DB, Robinson PA, Overbay CB, Richman DD. Factors determining sustained antiviral response to nevirapine (abstract #22). Proceedings of the Fourth International Workshop on HIV Drug-Resistance, Sardinia, Italy, July 6-9, 1995.
32. Cavert W, Coombs RW, Grimes J, Kuritzkes D, Johnson V, Kappes J, Stein D, Beatty C, Erice A, Winters M, Katzenstein D, Johnson E, Rojo E, Mirabile M, Elbeik T, Tsiatis B, Corey L, and ACTG Protocol 194 Clinics and Virology Laboratories. The therapeutic significance of switching to ddl or adding ddl in subjects with ZDV resistant HIV-1 (abstract #41). Proceedings of the Fourth International Workshop on HIV Drug-Resistance, Sardinia, Italy, July 6-9, 1995.
33. Crumpacker C, Welles S, Yen-Lieberman B, Demeter L, Japour A, Smeaton L, Johnson V, Kuritzkes D, D'Aquila R, Reichelderfer P, Richman D, Reichman R, McLaren C, Todd J, Kwok S, Coombs R, and Jackson B for the ACTG Clinical Trials Group Protocol 116A/116B/117 Team. Correlation of plasma HIV-1 RNA level and development of resistance mutations to AZT and ddl with disease progression in patients with advanced HIV-1 disease and little or no AZT therapy (abstract #42). Proceedings of the Fourth International Workshop on HIV Drug-Resistance, Sardinia, Italy, July 6-9, 1995.
34. Demeter L, Erice A, Mayers D, Fitzgibbon J, D'Aquila R, Arens M, Fisher E, Shafer R, Zhao Y, Huang D, Johnson V, Richman D, Rasheed S, Kuritzkes D, Reichelderfer P, Japour A, and the ACTG Genotypic Resistance Working Group. Interlaboratory concordance of DNA sequence analysis of the HIV-1 reverse transcriptase (RT) (abstract #1284). Proceedings of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, California, September 17-20, 1995.
35. Bartlett JA, Johnson VA, Quinn JB, Benoit SL, Rubin M and the NUCA 3002 Study Group. Long-term safety and efficacy of lamivudine (LMV) plus zidovudine (ZDV) compared with zalcitabine (ddC) plus ZDV in ZDV-experienced patients with absolute CD4+ cells = 100-300/mm³ (abstract #321). Proceedings of the 3rd Conference on Retroviruses and Opportunistic Infections, Washington, D.C., January 28-February 1, 1996.
36. Johnson VA, Quinn JB, Benoit SL, Wagner SF, Overbay CB, Wagner JR, Bartlett JA, Fallon MA, Cammack N, Rubin M. Drug resistance and viral load in NUCA 3002: lamivudine (3TC) (high or low dose)/zidovudine (ZDV) combination therapy versus ZDV/dideoxycytidine (ddC) combination therapy in ZDV-experienced (\geq 24 weeks) patients (CD4 cells 100-300/mm³) (abstract #199). Proceedings of the 3rd Conference on Retroviruses and Opportunistic Infections, Washington, D.C., January 28-February 1, 1996.

37. Johnson VA, Bassett RL, Stanley KE, Saag MS, Fischl MA, and the ACTG 259 Study Team and Virology Laboratories. Predictors of syncytium-inducing viral phenotype in a phase II double-blind trial of SC-49483 plus ZDV vs. ZDV (abstract #78). Proceedings of the Fifth International Workshop on HIV Drug Resistance, Whistler, Canada, July 3-6, 1996.
38. Johnson VA, Overbay CB, Koel JL, Nail CD, Bartlett JA, Cammack N, Quinn JB, Johnson J, Keller AL, Rubin M, Hazelwood JD. Drug resistance, viral load, and SI phenotype in NUCA 3002: combined 3TC/ZDV therapy over a maximum of 52 weeks in ZDV-experienced (≥ 24 weeks) patients ($CD4 + 100-300$ cells/mm³) (abstract #58). Proceedings of the Fifth International Workshop on HIV Drug Resistance, Whistler, Canada, July 3-6, 1996.
39. Fiscus SA, Mayers DL, Weislow O, Hazelwood JD, and Johnson VA. Prevalence of perinatal transmission of ZDV-resistant HIV-1 isolates among infants born in North Carolina: 1993-1996 (abstract #92). Proceedings of the Fifth International Workshop on HIV Drug Resistance, Whistler, Canada, July 3-6, 1996.
40. Johnson VA, Overbay CB, Koel JL, Nail CD, Bartlett JA, Quinn JB, Johnson J, Keller AL, Rubin M, Hazelwood JD. Drug resistance, viral load, and SI phenotype in NUCA 3002: combined 3TC/ZDV therapy over a maximum of 52 weeks in ZDV-experience (≥ 24 weeks) patients ($CD4 = 100-300/mm^3$) (abstract #402). Proceedings of the Fourth Conference on Retroviruses and Opportunistic Infections, Washington, DC, January 22-26, 1997.
41. Johnson VA, Bassett RL, Stanley KE, Saag MS, Fischl MA, and the ACTG 259 Study Team and Virology Laboratories. Predictors of syncytium-inducing viral phenotype in a phase II double-blind trial of SC-49483 plus ZDV vs. ZDV (abstract #227). Proceedings of the Fourth Conference on Retroviruses and Opportunistic Infections, Washington, DC, January 22-26, 1997.
42. Patick AK, Kuritzkes D, Johnson VA, Shugarts D, Bakhtiari M, Potts KE, Farnsworth A, Anderson R, Duran M, Markowitz M, Winters M, Merigan T, Ho D, and Richman D. Genotypic and phenotypic analyses of HIV-1 variants isolated from patients treated with nelfinavir and other protease inhibitors (abstract #18). Proceedings of the First International Workshop on HIV Drug Resistance, Treatment Strategies and Eradication, St. Petersburg, FL, June 25-28, 1997.
43. Eron JJ, St. Clair M, Gilbert C, Phillips AN, Keller A, Johnson J, Johnson VA. Rebound of plasma HIV-1 RNA after discontinuation of long-term 3TC/ZDV (abstract #97). Proceedings of the First International Workshop on HIV Drug Resistance, Treatment Strategies and Eradication, St. Petersburg, FL, June 25-28, 1997.
44. Johnson VA, Nail CD, Hazelwood JD, Marangos M, Smith R, Thompson M, Koel JL. Multidrug-resistant HIV-1 isolates from patients with rising plasma viral burden

during double or triple combination therapy in clinical practice (abstract #77). Proceedings of the First International Workshop on HIV Drug Resistance, Treatment Strategies and Eradication, St. Petersburg, FL, June 25-28, 1997.

45. Johnson VA, Kuritzkes DR, Richman DD, Hirsch MS, Fischl MA, DeGruttola V, D'Aquila RT for the ACTG 241 Virology Team. HIV-1 drug resistance and virologic failure during combination therapy with nevirapine (NVP), zidovudine (ZDV), and didanosine (ddI) (abstract #58). Proceedings of the First International Workshop on HIV Drug Resistance, Treatment Strategies and Eradication, St. Petersburg, FL, June 25-28, 1997.
46. D'Aquila RT, Sutton L, Savara A, Hughes MD, Johnson VA. CCR5/ccr5 heterozygosity: A selective pressure for the syncytium-inducing (SI) HIV-1 phenotype (abstract #95). Proceedings of the First International Workshop on HIV Drug Resistance, Treatment Strategies and Eradication, St. Petersburg, FL, June 25-28, 1997.
47. Hazelwood JD, Koel JL, Nail CD, Marangos M, Smith R, Miles S, Thompson M, Johnson, VA. Multidrug-resistant HIV-1 isolates from patients with rising plasma viral burden during double or triple combination therapy in clinical practice (abstract #421). Proceedings of the 5th Conference on Retroviruses and Opportunistic Infections, Chicago, Illinois, February 1-5, 1998.
48. Kuritzkes DR, Marschner IC, Johnson VA, Bassett RL, Eron JJ, Fischl MA, Boone G, Skovronski K, Wood K, Bell DL, Petrinelli CB, Sommadossi JP and the ACTG 306 Study Team. A randomized, double-blind, placebo-controlled trial of lamivudine (3TC), in combination with zidovudine (ZDV), stavudine (d4T), or didanosine (ddI) in treatment naive patients (abstract #1). Proceedings of the 5th Conference on Retroviruses and Opportunistic Infections, Chicago, Illinois, February 1-5, 1998.
49. Günthard H, Wong J, Leigh Brown A, D'Aquila R, Ignacio C, Johnson V, Kuritzkes D, Richman D. Higher selection pressure from antiretroviral drugs in vivo results in increased evolutionary distance (abstract #546a). Proceedings of the 5th Conference on Retroviruses and Opportunistic Infections, Chicago, Illinois, February 1-5, 1998.
50. Leigh Brown AJ, D'Aquila RT, Johnson VA, Kuritzkes DR, Richman DD. Baseline sequence clusters predict response to combination therapy in ACTG 241 (abstract #704). Proceedings of the 5th Conference on Retroviruses and Opportunistic Infections, Chicago, Illinois, February 1-5, 1998.
51. Schuurman R, Demeter L, Reichelderfer P, Tijnagel J, De Groot T, Boucher C on behalf of the ENVA laboratories, the Sequencing Working Group and participating laboratories. World-wide evaluation of DNA sequencing approaches for identification of drug resistance mutations in the HIV-1 reverse transcriptase (abstract #532). Proceedings of the 5th Conference on Retroviruses and

Opportunistic Infections, Chicago, Illinois, February 1-5, 1998.

52. Fiscus S, Adimora AA, Schoenbach VJ, Wilfert C, Johnson VA, and the NC-Children's AIDS Network NC. Can zidovudine monotherapy continue to reduce perinatal HIV transmission? The North Carolina Experience 1993-1997 (abstract #33162). Proceedings of the 12th World AIDS Conference, Geneva, Switzerland, June 28-July 3, 1998.
53. Günthard HF, Wong JK, Leigh Brown AJ, D'Aquila RT, Johnson VA, Kuritzkes D, Richman DD. Nucleoside RT-inhibitor and NNRTI combination therapy drives evolution of HIV-1 pol resulting in increased evolutionary distances (abstract #20). Proceedings of the Second International Workshop on HIV Drug Resistance and Treatment Strategies, Lake Maggiore, Italy, June 24-27, 1998. Antiviral Therapy 1998;3(Suppl 1):16-7.
54. Wu X, Lui H, Decker J, Johnson VA, Shaw GM, Kabat D, Kappes JC. A novel cell-based approach for analyzing the drug sensitivity of primary HIV-1 isolates (abstract #61). Proceedings of the Second International Workshop on HIV Drug Resistance and Treatment Strategies, Lake Maggiore, Italy, June 24-27, 1998. Antiviral Therapy 1998;3(Suppl 1):41-2.
55. Leigh Brown AJ, D'Aquila RT, Johnson VA, Kuritzkes DR, Richman DD. Baseline sequence clusters predict response to combination therapy in ACTG 241 (abstract #50). Proceedings of the Second International Workshop on HIV Drug Resistance and Treatment Strategies, Lake Maggiore, Italy, June 24-27, 1998. Antiviral Therapy 1998;3(Suppl 1):35.
56. Leigh Brown AJ, Günthard HF, Precious HM, D'Aquila RT, Johnson VA, Kuritzkes DR, Richman DD. Baseline sequence clusters predict response to combination antiretroviral therapy in ACTG 241 (abstract #I-831). Proceedings of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, California, September 24-27, 1998.
57. Kuritzkes DR, Marschner IC, Johnson VJ, Bassett RL, Eron JJ, Bell DL, Wood K, Sommadossi JP, Morse E, Pettinelli CB for the Adult ACTG 370 Study Team. Continued lamivudine (3TC) vs delavirdine (DLV) in combination with indinavir (IDV) and zidovudine (ZDV) or stavudine (d4T) in 3TC-experienced patients (abstract #488). Proceedings of the 6th National Conference on Retroviruses and Opportunistic Infections, Chicago, IL, January 31-February 4, 1999.
58. Precious H, Leigh Brown AJ, Günthard HF, Wong JK, D'Aquila RT, Johnson VA, Kuritzkes DR, Richman DD. A multiple regression model predicting response to combination therapy from baseline sequence data identifies amino acid sites not previously associated with resistance (abstract #14). Proceedings of the 6th National Conference on Retroviruses and Opportunistic Infections, Chicago, IL, January 31-February 4, 1999.

59. Katlama C, Murphy R, Johnson V, Squires K, Horban A, Gatell J, Clotet B, Staszewski S, vanLeeuwen R, Clumeck N, Moroni M, Pavia A, Schmidt J, Gonzalez-Lahoz J, Antunes F, Gulick R, Banhegyi D, Montaner J, Calvez V, Sommadossi J-P, Lange J. The Atlantic Study: A randomized open-label study comparing two protease inhibitor (PI)-sparing antiretroviral strategies versus a standard PI-containing regimen (abstract #18). Proceedings of the 6th National Conference on Retroviruses and Opportunistic Infections, Chicago, IL, January 31-February 4, 1999.
60. Johnson VA, Woods C, Hamilton CD, Fiscus SA. Vertical transmission of an HIV-1 variant resistant to multiple reverse transcriptase and protease inhibitors (abstract #266). Proceedings of the 6th National Conference on Retroviruses and Opportunistic Infections, Chicago, IL, January 31-February 4, 1999.
61. Precious HM, Gunthard HF, Wong JK, D'Aquila RT, Johnson VA, Kuritzkes DR, Richman DD, Leigh Brown AJ. Long-term response to antiretroviral therapy is associated with baseline variation at a novel amino site in HIV-1 reverse transcriptase (abstract #90). Proceedings of the 3rd International Workshop on HIV Drug Resistance and Treatment Strategies, San Diego, CA, June 23-26, 1999.
62. Johnson VA, Koel JL, Rhodes RA, Hazelwood JD, Fiscus SA, Whitcomb JM, Parkin NT, Petropoulos CJ. Comparison of phenotypic and genotypic drug resistance testing results obtained by recombinant virus (plasma) and conventional culture-based (PBMC) methodologies using clinical HIV isolates (abstract #103). Proceedings of the 3rd International Workshop on HIV Drug Resistance and Treatment Strategies, San Diego, CA, June 23-26, 1999.
63. Hazelwood JD, Hoesley CJ, Squires KE, Johnson VA. Detection of RT and PR resistance in genital tract and plasma viruses from an HIV-infected woman receiving highly active antiretroviral triple therapy: A case report (abstract #139). Proceedings of the 3rd International Workshop on HIV Drug Resistance and Treatment Strategies, San Diego, CA, June 23-26, 1999.
64. Murphy RL, Katlama C, Johnson V, Squires K, Horban A, Gatell JM, Clotet B, Staszewski S, Van Leeuwen R, Clumeck N, Moroni M, Pavia AT, Schmidt SE, Gonzalez-Lahoz J, Antunes F, Gulick R, Banhegyi D, Montaner JSG, Sommadossi JP, Lange J. The Atlantic Study: a randomized, open-label trial comparing two protease inhibitor (PI)-sparing antiretroviral strategies versus a standard PI-containing regimen, 48 week data (abstract #LB-22). Proceedings of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, California, September 26-29, 1999.
65. Call S, Westfall A, Cloud G, Johnson V, Raper J, Stewart K, Hellman N, Saag M. Predictive value of HIV phenotypic susceptibility testing in a clinical cohort (abstract #LB-17). Proceedings of the 39th Interscience Conference on Antimicrobial Agents

and Chemotherapy, San Francisco, California, September 26-29, 1999.

66. Gatell J, Murphy R, Katlama C, Johnson V, Squires K, Horban A, Clotet B, Staszewski S, van Leeuwen R, Clumeck N, Moroni M, Pavia A, Schmidt R, Gonzalez- Lahoz J, Antunes F, Gulick R, Banhegyi D, Montaner J, Sommadossi J-P, Lange J. The Atlantic study: a randomized, open-label trial comparing two protease inhibitor (PI)-sparing antiretroviral strategies versus a standard PI-containing regimen, 48 week data. Proceedings of the BCCAT Lisbon October 1999 Meeting.
67. Hanna GJ, Johnson VA, Kuritzkes DR, Richman DD, Leigh Brown AL, D'Aquila RT. Patterns of resistance mutations selected by treatment of HIV-1 infection with zidovudine (ZDV), didanosine (ddI) and nevirapine (NVP)(abstract #31). Proceedings of the 37th Annual Meeting of the Infectious Disease Society of America, Philadelphia, Pennsylvania, November 18-21, 1999.
68. Johnson V, Whitcomb J, Petropoulos C, Bassett R, Hellman N, Rosandich M, Marschner I, Kuritzkes D. Use of a recombinant virus assay to determine stavudine susceptibility in HIV-1 from patients treated with stavudine monotherapy (abstract #733). Proceedings of the 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, California, January 30-February 2, 2000.
69. Kuritzkes DR, Bassett RL, Johnson VA, Marschner IC, Eron JJ, Wood K, Sommadossi JP, Pettinelli CB for the Adult ACTG 370 Study Team. Continued lamivudine (3TC) vs delavirdine (DLV) in combination with indinavir (IDV) and zidovudine (ZDV) or stavudine (d4T) in 3TC-experienced patients: 48-week follow-up of ACTG 370 (abstract #525). Proceedings of the 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, California, January 30-February 2, 2000.
70. Moore JD, Acosta EP, Zhou X-J, Kuritzkes D, Johnson V, Sommadossi J-P. Plasma and intracellular triphosphate (NRTI-TP) concentrations of ZDV, d4T, and 3TC in patients with HIV infection (abstract #96). Proceedings of the 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, California, January 30-February 2, 2000.
71. Hanna G, Johnson V, Kuritzkes D, Richman D, Martinez-Picado J, D'Aquila R, and ACTG 241 Team. Sequencing by hybridization versus cycle sequencing for genotyping HIV-1 reverse transcriptase (abstract #791). Proceedings of the 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, California, January 30-February 2, 2000.
72. Johnson VA, Bassett RL, Koel JL, Rhodes RA, Young RK, Barrett H, and Kuritzkes DR for the ACTG Protocol 370 Team. Selection of zidovudine resistance mutations by zidovudine or stavudine-based regimens and relationship to subsequent virological response in ACTG 370 (abstract #57). Proceedings of the 4th

International Workshop on HIV Drug Resistance & Treatment Strategies, Sitges, Spain, June 12-16, 2000.

73. Ross LL, Liao Q, Johnson VA, Call S, Pham S, Tolson J, Gao H, Larder B, Hertogs K, Saag MS. The impact of HIV-1 drug-resistance mutations and phenotypic resistance profile on virological response to salvage therapy in a community setting (abstract #93). Proceedings of the 4th International Workshop on HIV Drug Resistance & Treatment Strategies, Sitges, Spain, June 12-16, 2000.
74. Murphy R, Katlama C, Autran B, Belsey E, Harris M, Montaner JSG, Pollard R, Hellinger J, Squires K, Calvez V, Gulick R, Sommadossi JP, Pavia A, Youle M, Schacker T, Berzins B, O'Gorman M, Johnson V, Landay A. The effects of hydroxyurea or placebo combined with efavirenz, didanosine, and stavudine in treatment naïve and experience patients: preliminary 24 week results from the 3d study. Proceedings of the XIII International AIDS Conference, Durban, South Africa, July 9-14, 2000.
75. Coughlan ME, Sommadossi J-P, Many WJ, Saag MS, Johnson VA. Lactic acidosis in hospitalized HIV-infected patients treated with nucleoside reverse transcriptase inhibitors (abstract #377). Proceedings of the 38th Annual Meeting of the Infectious Diseases Society of America, New Orleans, Louisiana, September 7-10, 2000.
76. Johnson VA, Call SA, Westfall AO, Cloud GA, Acosta EP, Tolson JM, Larder BA, Saag MS. Predictive value of genotypic resistance testing as interpreted by experts and a virtual phenotype (abstract #1259). Proceedings of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario, Canada, September 17-20, 2000.
77. Ross L, Liao Q, Johnson VA, Call S, Pham S, Tolson J, Gao H, Larder B, Hertogs K, Saag MS. Impact of HIV-1 drug-resistance mutations and phenotypic resistance profile on virologic response to salvage therapy in an observational cohort (abstract #1260). Proceedings of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario, Canada, September 17-20, 2000.
78. Johnson VA, Bassett RL, Koel JL, Rhodes RA, Young RK, Barrett H, Kuritzkes DR. Selection of zidovudine (ZDV) resistance mutations by ZDV- or stavudine (d4T) based regimens and relationship to subsequent virologic response in ACTG 370 (abstract #2111). Proceedings of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario, Canada, September 17-20, 2000.
79. Call SA, Johnson VA, Westfall AO, Acosta EP, Cloud GA, Ross LL, Larder BA, Saag MS. Degree of agreement among interpretation of genotypic resistance testing results in a cohort of ART-experienced individuals (abstract #2118). Proceedings of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario, Canada, September 17-20, 2000.

80. Johnson V, Delaugerre C, Hazelwood J, Berzins B, Belsey E, Rhodes R, Calvez V, Katlama C, Murphy R for the International 3D Study Team. Viral resistance results from the international, multicenter, randomized, placebo-controlled, 48-week study of hydroxyurea (HU) or placebo combined with efavirenz (EFV), didanosine (ddl), and stavudine (d4T) in treatment naïve and experienced patients (abstract #445). 8th Conference on Retroviruses and Opportunistic Infections, Chicago, IL, February 4-8, 2001.
81. Kuritzkes DR, Ickovics J, Bassett R, Hellmann N, and Johnson VA for the ACTG 370 Protocol Team. HIV-1 drug resistance and medication adherence in patients receiving nucleoside reverse transcriptase inhibitors (abstract #84). Proceedings of the 5th International Workshop on HIV Drug Resistance & Treatment Strategies, June 4-8, 2001.
82. Johnson V, Abrams G, Nail C, Desmond R, van Leeuwen D, Bloomer J. Quantification of hepatitis C virus (HCV) RNA levels in plasma, peripheral blood mononuclear cells (PBMC), and liver tissue in vivo (abstract #430). Proceedings of the 39th Annual Meeting of the Infectious Diseases Society of America, San Francisco, CA, October 26, 2001.
83. Abrams GA, Johnson VA, Nail CD, Jhala NC, van Leeuwen D, Fallon MB, McGuire BM, Arguedas M, Bloomer JR. Quantification of hepatitis C virus (HCV) RNA levels in plasma, peripheral blood mononuclear cells (PBMC), and liver tissue (abstract #40574). Proceedings of the 52nd Annual Meeting of the American Association for the Study of Liver Disease (AASLD), Dallas, TX, November 9-13, 2001.
84. Grant RM, Lloyd RM, Johnson VA, Sullivan JL, Swanstrom R, Holodniy M, Reid C, Morgan G, Winslow DL. Reproducibility and accuracy of a novel kit-based genotyping assay for HIV-1 drug resistance. Submitted for presentation at the 9th Conference on Retroviruses and Opportunistic Infections, Seattle, WA, November 9-13, 2001.

PRESENTATIONS

Scientific Papers Presented at National and International Meetings:

- | | |
|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1988 | Speaker, First NIH/NIAID National Cooperative Drug Discovery and Development Meeting, Oakland, California, October 30-November 2 |
| 1988 | Lecturer, Second Triennial Symposium on New Directions in Antiviral Chemotherapy, University of California San Francisco, November 3-5 |
| 1989 | Lecturer, Fifth Annual Clinical Virology Symposium and Annual Meeting, Pan American Group for Rapid Viral Diagnosis, University of South Florida College of Medicine, Tampa, Florida, April 30-May 3 |

- 1989 Speaker, Annual Meeting of the Laboratory of Tumor Cell Biology, National Cancer Institute, Bethesda, Maryland, August 20-26
- 1990 Speaker, Sixth International Conference on AIDS, San Francisco, California, June 20-24
- 1992 Moderator and Discussant, Second Workshop on Viral Resistance, Food and Drug Administration, National Institute of Allergy and Infectious Diseases, Walter Reed Army Institute of Research, Herndon, Virginia, May 13-15
- 1992 Moderator and Plenary Speaker, HIV Drug-Resistance Workshop, Noordwijk, the Netherlands, July 16-18
- 1992 Moderator and Discussant, Combination Antiretroviral Therapies Poster Session, VIII International Conference on AIDS/III STD World Congress, Amsterdam, the Netherlands, July 19-24
- 1992 Moderator, Antiretroviral Agents in Preclinical Development Session, 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy, Anaheim, California, October 11-14
- 1992 Speaker, 5th National Forum on AIDS, Hepatitis, and Other Blood-Borne Diseases, National Foundation for Infectious Diseases, Atlanta, Georgia, March 29-April 1
- 1993 Moderator and Plenary Speaker, Second International Workshop on HIV Drug-Resistance, Noordwijk, the Netherlands, June 3-5
- 1993 Speaker, IXth International Conference on AIDS/IVth STD World Congress Berlin, Germany, June 6-11
- 1993 Plenary Speaker, Combination Therapies for HIV Infection, 5th International Conference of the National Cooperative Drug Discovery Groups - HIV (NCDDG-HIV), Washington, D.C., July 11-16
- 1993 Moderator, Controversial Topics in Retroviral Resistance, The First National Conference on Human Retroviruses and Related Infections, National Foundation for Infectious Diseases and the American Society for Microbiology and the National Institutes of Health and the Center for Disease Control, Washington, D.C., December 12-16
- 1995 Moderator, and Plenary Speaker, Fourth International Workshop on HIV Drug Resistance, Sardinia, Italy, July 6-9
- 1995 Plenary Speaker, Mechanisms of HIV-1 Drug Resistance, Southeastern Branch American Society for Microbiology 1995 Annual Meeting,

Birmingham, Alabama, November 9-11

- 1996 Moderator, Viral Hepatitis Session, NIH/NIAID Collaborative Antiviral Study Group, Bethesda, MD, March 13-15
- 1996 Speaker, New Developments in the Management of HIV and AIDS, The University of Chicago, Chicago, Illinois, April 20
- 1996 Speaker and Session Chair, Proceedings of the Fifth International Workshop on HIV Drug-Resistance, Whistler, British Columbia, Canada, July 3-6
- 1996 Speaker, 90th Annual Scientific Assembly, HIV/AIDS: An Evaluation and Management Update, Southern Medical Association, Baltimore, Maryland, November 20-24
- 1997 Moderator and Plenary Speaker, International Workshop on HIV Drug Resistance, Treatment Strategies, and Eradication, St. Petersburg, Florida, June 25-28.
- 1997 Invited Plenary Speaker, 22nd Group Meeting of the Terry Bein Community Programs for Clinical Research on AIDS, Washington, DC, February 6-8, 1997
- 1997 Invited Plenary Speaker, Department of Veterans Affairs (VA) Employee Education System, Birmingham Center (EES, BC), "HIV/AIDS: Update in Clinical Care," Washington, D.C., September 22-23.
- 1998 Moderator, Slide Session #65 "Antiretroviral Chemotherapy", 5th Conference on Retroviruses and Opportunistic Infections, Chicago, Illinois, February 1-5
- 1998 Moderator, HIV/Hepatitis Session, NIH/NIAID Collaborative Antiviral Study Group, Washington, D.C., February 18-20
- 1998 Moderator, Long-Term Suppression/Eradication Strategies, 2nd International Workshop on HIV Drug Resistance & Treatment Strategies, Lake Maggiore, Italy, June 24-27
- 1998 Moderator, Antiretroviral Resistance, 12th World AIDS Conference, Geneva, Switzerland, June 28-July 3
- 1998 Moderator, Slide Session #063-I "Antiretroviral Resistance", 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, California, September 25
- 1998 Co-Moderator with Dr. John Mellors, "Meet-the-Professors" Session, Practical Issues in the Prevention and Management of the Resistance of HIV

- to Antiviral Agents, 36th Annual Meeting of the Infectious Diseases Society of America, Denver, CO, November 12-15
- 1998 Speaker, 6th National Conference on Retroviruses and Opportunistic Infections, Chicago, IL, January 31-February 4
- 1999 Moderator, Combination Therapy and Its Failure, 3rd International Workshop on HIV Drug Resistance and Treatment Strategies, San Diego, California, June 23-26
- 1999 Convener, Controversies in HIV Management. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 26-29
- 1999 Co-Moderator with Dr. Daniel Kuritzkes, "Meet-the-Professors" Session, HIV Drug Resistance" Session, 37th Annual Meeting of the Infectious Disease Society of America, Philadelphia, Pennsylvania, November 18-21
- 1999 Speaker, IAS-USA Interactive Session: Antiretroviral Therapy Decision Making In The Combination Therapy Era, 37th Annual Meeting of the Infectious Disease Society of America, Philadelphia, Pennsylvania, November 18-21
- 1999 Speaker, Genotyping and Phenotyping: An Overview of When it Can and Cannot Help with Clinical Decision Making, 1999 National Conference on Women and HIV/AIDS
- 2000 Speaker, Proceedings of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario, Canada, September 17-20, 2000.
- 2001 Co-Moderator with Dr. Andres R. Zolopa, "Meet-the-Professors" Session, HIV Resistance Testing, 39th Annual Meeting of the Infectious Diseases Society of America, San Francisco, CA, October 25-28
- 2001 Convener, Cutting Edge Issues in HIV Medicine, 39th Annual Meeting of the Infectious Diseases Society of America, San Francisco, CA, October 25-28

Invited Workshops at National Postgraduate Courses and Meetings and at Other Universities:

- 1991 Panel Member, Contractors' Workshop on Combination Therapies, Division of AIDS, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, September 19-20
- 1992 Participant, NIH AIDS Clinical Trials Group Virology Core Committee

Conference, Houston, Texas, October 1-2

- 1993 Moderator, Workshop on Drug Combination Testing for HIV, Division of AIDS-NIAID/NIH, Washington, D.C., July 14
- 1993 Moderator, AZT Resistance in Infants and Children, The Ariel Project of the Pediatric AIDS Foundation and National Institute of Allergy and Infectious Diseases, Santa Monica, California, August 30-31
- 1993 Moderator, Third Workshop on Viral Resistance, Division of AIDS-NIAID/DTB, Division of Antiviral Drug Products-FDA, and Division of Retrovirology-WRAIR, Gaithersburg, Maryland, September 19-22
- 1994 Opening Speaker, Third International Workshop on HIV Drug-Resistance, Kauai, Hawaii, August 2-5
- 1994 Opening Speaker, Stopping the Epidemic: Care of the HIV Child and Young Adult, Second Annual Conference, Palm Beach, Florida, October 13-15
- 1995 Speaker, AIDS Treatment Issues: Viral Load Measurements in Clinical Practice, Tufts University School of Medicine, Boston, Massachusetts, November 18
- 1996 Speaker, AIDS Treatment Issues: Combination Therapies and Viral Load Testing, Brown University School of Medicine and Tufts University School of Medicine, Boston, Massachusetts, December 7
- 1997 Invited Speaker, International Workshop on Salvage Therapy for HIV Infection, New Orleans, Louisiana, April 16-18
- 1999 Invited Speaker, The National Conference on Women and HIV/AIDS, Los Angeles, California, October 9-12

Invited Lectures at Local and Regional Courses and Meetings:

- 1993 Speaker, Improving the Management of HIV Disease: An Advanced Course in Antiretrovirals, Prophylaxis, and the Treatment of Opportunistic Diseases, International AIDS Society, Atlanta, Georgia, January 23
- 1993 Speaker, Optimal Management of HIV Disease; Clinical Conference, University of Alabama at Birmingham and Rush-Presbyterian-St. Luke's Medical Center, Fort Lauderdale, Florida, February 12-14
- 1994 Speaker, Optimal Management of HIV Disease; Clinical Conference II, University of Alabama at Birmingham and Rush-Presbyterian-St. Luke's Medical Center, Deerfield Beach, Florida, January 20-23

- 1994 Speaker, Improving the Management of HIV Disease: An Advanced Course in Antiretrovirals, Prophylaxis, and the Treatment of Opportunistic Diseases, The International AIDS Society-USA, Atlanta, Georgia, April 9
- 1994 Opening Speaker, Improving the Management of HIV Disease: An Advanced Course in Antiretrovirals, Prophylaxis, and the Treatment of Opportunistic Diseases, The International AIDS Society-USA, Miami, Florida, April 16
- 1995 Speaker, Improving the Management of HIV Disease: An Advanced Course in HIV Pathogenesis, Antiretrovirals, and the Prevention of Opportunistic Diseases, International AIDS Society-USA, Atlanta, Georgia, February 25
- 1997 Speaker, Improving the Management of HIV Disease: HIV Pathogenesis, Antiretrovirals, and Other Selected Issues in HIV Disease Management, The International AIDS Society - USA, Atlanta, Georgia, February 13
- 1998 Speaker, Improving the Management of HIV Diseases: An advanced course in HIV pathogenesis, The International AIDS Society - USA, Atlanta, Georgia, February 13
- 1998 Speaker, Improving the Management of HIV Disease: An advanced course in HIV pathogenesis, The International AIDS Society - USA, New Orleans, Louisiana, May 2
- 1999 Speaker, Improving the Management of HIV Disease: An Advanced Course in HIV Pathogenesis, Antiretrovirals, and Other Selected Issues in HIV Disease Management, The International AIDS Society - USA, Los Angeles, California, February 20
- 1999 Speaker, Optimal Management of HIV Disease: Clinical Conference VII, University of Alabama at Birmingham School of Medicine and Rush-Presbyterian-St. Luke's Medical Center, Fort Lauderdale, Florida, February 25-28
- 2000 Speaker, Improving the Management of HIV Disease: An Advanced Course in HIV Pathogenesis, Antiretrovirals, and Other Selected Issues in HIV Disease Management, The International AIDS Society - USA, Atlanta, Georgia, February 11
- 2000 Speaker, Improving the Management of HIV Disease: An Advanced Course in HIV Pathogenesis, Antiretrovirals, and Other Selected Issues in HIV Disease Management, The International AIDS Society - USA, Dallas, Texas, May 8
- 2000 Plenary Speaker, Northern New England Infectious Diseases Society Tenth Annual Meeting, Portsmouth, NH, May 14

- 2000 Speaker, Improving the Management of HIV Disease: An Advanced Course in HIV Pathogenesis, Antiretrovirals, and Other Selected Issues in HIV Disease Management, The International AIDS Society - USA, Washington, D.C., May 25
- 2002 Speaker, Optimal Management of HIV Disease: Clinical Conference X, University of Alabama at Birmingham School of Medicine and Rush-Presbyterian-St. Luke's Medical Center, Fort Lauderdale, Florida, March 14-17
- 2002 Speaker, Improving the Management of HIV Disease: An Advanced Course in HIV Pathogenesis, Antiretrovirals, and Other Selected Issues in HIV Disease Management, The International AIDS Society - USA, Atlanta, GA, March 18

Miscellaneous Educational Activities:

- 1996 Cedars-Sinai Medical Center and UCLA CARE Center and AIDS Institute HIV-related Continuing Medical Education Teleconference Series
- 1998-1999 University of Alabama at Birmingham School of Medicine National Faculty Member, The Art of HIV Management

**APPEARS THIS WAY
ON ORIGINAL**